5248242025-04-012025-06-305248242025-04-012025-06-30in-capmkt:OtherExpenses1Member5248242025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524824BALPHARMANOTLISTEDINE083D01012BAL PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-08-112025-07-29INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICLES2025-08-1116:30:002025-08-1117:15:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated658709000722200066593100036028500039847000-647060001480370004053400025204000114645000663846000208500002085000000020850000000208500002085000159209000100.130.13000.130.131The above un audited standalone financial results of the companyhave been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11.08.2025 <BR> <BR> 2 The Consolidated financial results has been prepared in accordance with the Companies Indian Accounting Standards Rules, 2015 IND AS 2015 prescribned under section 133 of the Companies Act 2013 tread with relevant rules issued thereunder and other recognized accounting policies to the extend applicable. The unaudited consolidated financial results relate topn Bal Pharma Limited and its subsidiaries Together constitute as group joint venture and associates and are prepared by applying IND AS 110 Consolidate Financial Statements and IND AS 28 Investments in associates and joint ventures <BR> <BR> 3 The group has not received any intimation or information with regard to its vendors registration as a Micro Small and Medium enterprises Accordingly the entire dues to vendors has been classified as payable to other tham MSME <BR> <BR> 4 The Company has a outstanding recoverability of Rs 969.17 Lakhs and Rs 155. 22 Lakhsfrom its subsidiaries Lifezen Healthcare Pvt Ltd and Balance Clinics LLP The said subsidiaries have incurred losses and have a negative networth However the management is confident that with infusion of additional funds introduction of new brands and renewed marketing internal restructuring the companies can be revived and amounts be recovered <BR> <BR> 5 The figures for the year ended March 31, 2025 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter of the relevant financial year which were subject to the limited review by the statutory auditor of the Company <BR> <BR> 6. The Company has only one reportable segment namely '' Pharmaceuticals ''. <BR> <BR> 7. Golden Drugs Pvt Ltda wholly owned subsidiary of the Company is merged with Bal Pharma Ltd pursuant to NCLT order dated 26.03.2025. <BR> <BR> 8. Previous period figures have been regrouped/ rearranged wherever considered necessary to confirm to the period presentation. Other Expenses114645000UnauditedtrueSSJNBCompanytrue2026-03-31